DrugMonitor™ Anti-Concizumab Antibody (VS-1224-YC301) (CAT#: VS-1224-YC301)

Concizumab has participated in trials for treating hemophilia A and congenital bleeding disorders. The DrugMonitor™ Anti-Concizumab Antibody (VS-1224-YC301) is an anti-drug antibody (ADA) against Concizumab. This drug-based antibody is raised in mice immunized with the Concizumab. The anti-Concizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Concizumab in samples.

Specific Inquiry
  • Size:
  • Conjugation:
  • Purity:
  • Datasheet
  • MSDS
  • COA

Specifications

  • Host Animal
  • Mouse
  • Specificity
  • Concizumab
  • Target
  • Concizumab
  • Immunogen
  • Concizumab
  • Type
  • Mouse IgG
  • Species Reactivity
  • Human
  • Purity
  • >95%
  • Purification
  • Protein G
  • Applications
  • ELISA, PK/PD, ADA control
  • Format
  • Liquid
  • Concentration
  • Batch-dependent
  • Buffer
  • PBS, pH 7.4
  • Preservative
  • No preservatives
  • Storage
  • Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
  • Generic name
  • Concizumab
  • Related Disease
  • Hemophilia A and congenital bleeding disorders

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "concizumab"

Anti-TFPI Recombinant Antibody (Concizumab)
Recombinant humanized antibody expressed in CHO binding to human TFPI. Concizumab is a monoclonal IgG4 antibody (mAb) that binds to the Kunitz-type protease inhibitor (KPI) 2 domain of TFPI thereby blocking the interaction of this domain with the active site of FXa.
Afuco™ Anti-TFPI ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-734)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human TFPI. It is a monoclonal IgG4 antibody (mAb) that binds to the Kunitz-type protease inhibitor (KPI) 2 domain of TFPI thereby blocking the interaction of this domain with the active site of FXa.

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for VS-1224-YC301. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare